ADVVF 股利： Advicenne SA 收益洞察

Q: Advicenne SA 的關鍵財務報表是什麼？

根據最新的財務報表（Form-10K），Advicenne SA 的總資產為 $9，淨損失為 $-6

Q: ADVVF 的關鍵財務比率是什麼？

Advicenne SA 的流動比率為 0.32，淨利潤率為 -300，每股銷售為 $0.16。

Q: Advicenne SA 的收入按細分市場或地理位置如何劃分？

Advicenne SA 最大收入來源為 Pharmaceuticals，在最近的收益報告中收入為 4,973,000。就地區而言，European Union 是 Advicenne SA 的主要市場，收入為 4,708,000。

Q: Advicenne SA 是否盈利？

無，根據最新的財務報表，Advicenne SA 的淨損失為 $-6

Q: Advicenne SA 有負債嗎？

是的，Advicenne SA 的負債為 28

Q: Advicenne SA 的流通股有多少？

Advicenne SA 的總流通股為 12.29

首頁

股票

ADVVF

ADVVF 財務

Advicenne SA

0%

$0

收盤價：Jan 16, 16:00:00 GMT-5

0%

$0

盤後：Jan 16, 20:00:00 GMT-5

概觀預測收益股利財務狀況

關鍵數據

前收市價

開盤價

當日範圍

52週區間

交易量

平均成交量

每股盈餘 (TTM)

股息收益率

市值

什麼是 ADVVF？

Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.

功能特性

交易策略

資源

市場

收入

資產負債表

現金流量

年度

每季

ADVVF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	2	2	2	2	2	2
營收年增率 (YoY)	-33%	0%	0%	0%	0%	100%
營收成本	1	6	6	8	10	12
毛利	1	-3	-3	-5	-8	-10
銷售、一般及管理費用	1	5	5	1	2	2
研發	2	--	2	2	3	2
營業費用	5	7	4	4	4	3
其他非營業收入 (費用)	0	--	0	0	0	0
稅前淨利	-4	-6	-7	-11	-12	-14
所得稅費用	0	0	0	0	0	0
淨利	-4	-6	-7	-11	-12	-14
淨利成長	-50%	-14%	-36%	-8%	-14%	0%
稀釋後流通股數	12.29	12.29	12.29	10.12	9.44	8.59
股數年變動 (YoY)	0%	0%	21%	7%	10%	5%
每股盈餘 (稀釋)	-0.4	-0.52	-0.61	-1.13	-1.31	-1.72
每股盈餘成長率	-43%	-14%	-46%	-14%	-24%	-1%
自由現金流	--	--	-7	-9	-12	-12
每股自由現金流	--	--	--	--	--	--
毛利率	50%	-150%	-150%	-250%	-400%	-500%
營業利益率	-200%	-550%	-400%	-500%	-600%	-700%
淨利率	-200%	-300%	-350%	-550%	-600%	-700%
自由現金流利潤率	--	--	-350%	-450%	-600%	-600%
EBITDA	--	-9	-8	-10	-12	-14
EBITDA 利潤率	--	-450%	-400%	-500%	-600%	-700%
EBITDA 中的折舊與攤銷	--	2	0	0	0	0
EBIT	-4	-11	-8	-10	-12	-14
EBIT 利潤率	-200%	-550%	-400%	-500%	-600%	-700%
有效稅率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Advicenne SA 的關鍵財務報表是什麼？



ADVVF 的關鍵財務比率是什麼？



Advicenne SA 的收入按細分市場或地理位置如何劃分？



Advicenne SA 是否盈利？



Advicenne SA 有負債嗎？



Advicenne SA 的流通股有多少？



Advicenne SA（ADVVF）價格

ADVVF 股價走勢圖